Skip to main content

Burning Rock Biotech Ltd

corporate_fare Company Profile

Burning Rock Biotech Ltd

BNR·NASDAQ·Industrial Applications And Services·CIK 0001792267

We aim to transform precision oncology and early cancer detection. We are China's leading NGS-based cancer therapy selection company. Our cancer therapy selection platform uses advanced proprietary technologies, a comprehensive product portfolio, and a two-pronged commercial infrastructure. This infrastructure addresses larger hospitals through an in-hospital model and smaller hospitals through a central laboratory model. Our advanced technology platform integrates proprietary cancer therapy selection technologies using both tissue and liquid biopsies, including assay biochemistry, bioinformatics, and a patented laboratory information management system. Our proprietary HS library preparation technology works with poor quality and limited volume samples and enables enhanced sensitivity, which is critical for NGS-based cancer therapy selection, especially in China. Our in-depth cancer genomics insights, accumulated from a large number of tests performed since inception, enable us to process and accurately analyze genomic information. We achieve a turnaround time of approximately six days for regular oncology products, approximately twenty-five days for MRD products, and approximately nine days for early detection products. We offer a broad spectrum of NGS-based products. Our NGS-based cancer therapy selection test products assist physicians in selecting effective therapy for cancer patients. We primarily offer 33 NGS-based cancer therapy selection and prognosis prediction tests applicable to a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples. Our core products, OncoCompass IO, OncoScreen IO, and OncoCompass Target, perform on par with global peers. We launched our MRD product, CanCatch, previously known as brPROPHET, in March 2022, which has demonstrated superior sensitivity and specificity to fixed panel in pre-operative ctDNA detection and post-operative MRD calling among relapsed patients.

Burning Rock Biotech Ltd (NASDAQ:BNR) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 7 items for BNR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-10, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for BNR spans 4, 6-K, 20-F.

Recent high-impact activity:

  • Burning Rock Q2 Revenue Falls 9%, Loss Widens on Lab Weakness
  • Director Han Yusheng Buys $6.18M in Open Market Shares
  • Burning Rock Biotech Reports Q1 2026 Revenue Decline and Increased Net Loss
  • Burning Rock Biotech Reports Significant Reduction in Net Loss and Operating Cash Burn, Achieves Dual Breakthrough Device Designation for Early Cancer Test
  • Director Han Yusheng Makes Substantial $5.47M Open Market Purchase of Burning Rock Biotech Shares

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
¥539.57M CNY
Net Income
-¥55.35M CNY
Op. Cash Flow
-¥28.44M CNY
Free Cash Flow
-¥33.69M CNY
Gross Profit
¥402.91M CNY
Operating Income
-¥54.84M CNY
Cash & Equivalents
¥478.39M CNY
Total Debt
¥200K CNY
Debt / Equity
0.00×
Net Margin
-10.3%
Source: 20-F · filed 2026-04-28 · accession 0001193125-26-183377

Short Interest & Short Volume

1.34 days to cover

FINRA reported short interest of 34,334 shares in BNR as of the October 30, 2026 settlement, a 6.9% decrease from the prior period — about 1.3 days to cover at its recent average daily volume. On November 20, 2026, 39.9% of BNR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)34,334 shares as of October 30, 2026
Change vs prior period▼ 6.9%
Days to cover1.34 at avg daily volume of 25,640
Daily short volume (FINRA facilities)39.9% of 4,894 shares on November 20, 2026
5-day average short volume30.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

BNR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with B →
$13.24
52-week range · as of 2026-07-02 $3.14 – $41.72
Market cap
$139.26M
Volume
27.9K (1.1× avg)
3-mo avg 24.8K
Live data · 2026-11-22 11:07 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BNR - Latest Insights

BNR
Sep 10, 2026, 7:29 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $13.24 info
Change: +$1.64 (+14%) info
Market Cap: $139.262M info
BNR
Jul 02, 2026, 8:30 AM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $8.96
Real-time Price: $13.24 info
Change: +$4.28 (+48%) info
Market Cap: $139.262M info
BNR
Jun 09, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $9.07
Real-time Price: $13.24 info
Change: +$4.17 (+46%) info
Market Cap: $139.262M info
BNR
Apr 28, 2026, 6:08 AM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $19.06
Real-time Price: $13.24 info
Change: -$5.82 (-31%) info
Market Cap: $139.262M info
BNR
Apr 02, 2026, 7:17 AM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $16.30
Real-time Price: $13.24 info
Change: -$3.06 (-19%) info
Market Cap: $139.262M info
BNR
Mar 12, 2026, 8:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $23.46
Real-time Price: $13.24 info
Change: -$10.22 (-44%) info
Market Cap: $139.262M info
BNR
Mar 12, 2026, 7:15 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $23.46
Real-time Price: $13.24 info
Change: -$10.22 (-44%) info
Market Cap: $139.262M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets